Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 8/20 | 0.59 |
| ▸ | WNT3A | P56704 | 8/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440716 | 0.90 | ATM (0.64) | CTNNB1WNT3AALDH1A1NPC1RAB9A | |
| SCHEMBL2237626 | 0.81 | MEN1 (0.76) | CTNNB1WNT3AMEN1KMT2AALDH1A1 | |
| SCHEMBL29458253 | 0.81 | MEN1 (0.76) | CTNNB1WNT3AMEN1KMT2AALDH1A1 | |
| SCHEMBL6486626 | 0.80 | CTNNB1 (0.66) | CTNNB1WNT3AMEN1KMT2AALDH1A1 | |
| SCHEMBL4865452 | 0.80 | CTNNB1 (0.66) | CTNNB1WNT3AMEN1KMT2AALDH1A1 | |
| SCHEMBL2601929 | 0.79 | ALDH1A1 (0.74) | CTNNB1WNT3AMEN1KMT2AALDH1A1 | |
| SCHEMBL4258312 | 0.78 | CTNNB1 (0.64) | CTNNB1WNT3AMEN1KMT2AALDH1A1 | |
| SCHEMBL13785040 | 0.78 | CTNNB1 (0.64) | CTNNB1WNT3AMEN1KMT2AALDH1A1 | |
| SCHEMBL7253369 | 0.78 | CTNNB1 (0.64) | CTNNB1WNT3AMEN1KMT2AALDH1A1 | |
| SCHEMBL1092123 | 0.78 | ATM (0.81) | CTNNB1WNT3AMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-11136336-B2 | Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20210107918-A1 | Novel Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
| WO-2021067967-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210101901-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | CAL POLY CORPORATION | 2021-04-08 | — | — | US | disclosed |
| EP-2430029-B1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| US-9499563-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-11-22 | — | — | US | disclosed |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2014-10-02 | — | — | US | disclosed |
| US-8785638-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-07-22 | — | — | US | disclosed |
| EP-2362876-B1 | THIENOTRIAZOLODIAZEPINE DERIVATIVES ACTIVE ON APO A | CIRCOMED LLC (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-03-08 | — | — | US | disclosed |
| US-20110230460-A1 | THIENOTRIAZOLODIAZEPINE DERIVATIVES ACTIVE ON APO A | CIRCOMED LLC (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2362876-A1 | THIENOTRIAZOLODIAZEPINE DERIVATIVES ACTIVE ON APO A | Circomed LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010130842-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010049466-A1 | THIENOTRIAZOLODIAZEPINE DERIVATIVES ACTIVE ON APO A | DYBLY AG (CH) | 2010-05-06 | — | — | WO | disclosed |
| EP-1261327-B1 | ADENOSINE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2005-04-27 | — | — | EP | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107918-A1 | Novel Thienopyrimidones | TRPA1, TRPV1, TRPV2 | CTNNB1 2844/4885WNT3A 4294/4885MEN1 3704/4885 |
| US-20110230460-A1 | THIENOTRIAZOLODIAZEPINE DERIVATIVES ACTIVE ON APO A | APOB, APOL1, NR1H2 | CTNNB1 1908/4885WNT3A 2021/4885MEN1 2158/4885 |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | CTNNB1 428/4885WNT3A 1171/4885MEN1 4860/4885 |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | CTNNB1 3788/4885WNT3A 3648/4885MEN1 4548/4885 |
| US-20210101901-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | PNPO, NOX3, G6PD | CTNNB1 4109/4885WNT3A 3430/4885MEN1 2655/4885 |
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | PNPO, NOX3, G6PD | CTNNB1 4109/4885WNT3A 3430/4885MEN1 2655/4885 |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | CTNNB1 3788/4885WNT3A 3648/4885MEN1 4548/4885 |
| US-11136336-B2 | Thienopyrimidones | TRPA1, TRPV1, TRPV2 | CTNNB1 2735/4885WNT3A 4313/4885MEN1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.